ETF
IBB
NASDAQiShares Biotechnology ETF (IBB)
The line runs 212.57 USD on 24 August through 199.73 USD on 20 November, on a scale from 190 to 230. Days the market did not trade hold the previous close, flat.
- 52-week range
- 160.46 USD – 221.19 USD
- Avg volume
- 125.0K
- Mentions, 30 days
- 5
- Net sentiment
- +0.12
as of Nov 20, 2026
What does iShares Biotechnology ETF (IBB) hold?
IBB holds 239 companies. The largest are Vertex Pharmaceuticals (8.1%), Amgen (7.8%), Gilead Sciences (6.8%). The ten biggest holdings make up 44.7% of the fund; the smallest 119 together make up 5.0%.
Portfolio at 30 June 2026, from the fund's SEC Form N-PORT filed 25 August 2026. Funds publish these about two months after each quarter ends, so the portfolio at 30 September 2026 is due by 29 November 2026. The filing
| # | Holding | Weight | Value |
|---|---|---|---|
| 1 | Vertex Pharmaceuticals, Inc. | 8.08% | $734m |
| 2 | Amgen, Inc. | 7.83% | $711m |
| 3 | Gilead Sciences, Inc. | 6.84% | $622m |
| 4 | Regeneron Pharmaceuticals, Inc. | 4.91% | $446m |
| 5 | Argenx SE | 3.76% | $342m |
| 6 | Alnylam Pharmaceuticals, Inc. | 3.12% | $284m |
| 7 | Natera, Inc. | 2.89% | $263m |
| 8 | Revolution Medicines, Inc. | 2.78% | $253m |
| 9 | Biogen, Inc. | 2.47% | $224m |
| 10 | Illumina, Inc. | 2.07% | $188m |
| 11 | Moderna, Inc. | 1.98% | $180m |
| 12 | Insmed, Inc. | 1.78% | $162m |
| 13 | BeOne Medicines Ltd. | 1.77% | $161m |
| 14 | Incyte Corp. | 1.75% | $159m |
| 15 | United Therapeutics Corp. | 1.73% | $158m |
| 16 | Roivant Sciences Ltd. | 1.43% | $130m |
| 17 | Neurocrine Biosciences, Inc. | 1.30% | $118m |
| 18 | Ascendis Pharma A/S | 1.29% | $117m |
| 19 | Genmab A/S | 1.12% | $102m |
| 20 | Exelixis, Inc. | 1.03% | $94m |
| 21 | Ionis Pharmaceuticals, Inc. | 1.00% | $91m |
| 22 | Bridgebio Pharma, Inc. | 0.98% | $89m |
| 23 | Medpace Holdings, Inc. | 0.95% | $86m |
| 24 | Madrigal Pharmaceuticals, Inc. | 0.91% | $83m |
| 25 | Bio-Techne Corp. | 0.86% | $78m |
| 26 | BioMarin Pharmaceutical, Inc. | 0.85% | $77m |
| 27 | Charles River Laboratories International, Inc. | 0.84% | $76m |
| 28 | Arrowhead Pharmaceuticals, Inc. | 0.84% | $76m |
| 29 | Axsome Therapeutics, Inc. | 0.82% | $75m |
| 30 | Cytokinetics, Inc. | 0.79% | $72m |
| 31 | Krystal Biotech, Inc. | 0.75% | $68m |
| 32 | Halozyme Therapeutics, Inc. | 0.72% | $65m |
| 33 | Praxis Precision Medicines, Inc. | 0.68% | $62m |
| 34 | Abivax SA | 0.67% | $61m |
| 35 | Alkermes plc | 0.67% | $61m |
| 36 | BioNTech SE | 0.66% | $60m |
| 37 | Vaxcyte, Inc. | 0.64% | $58m |
| 38 | Kymera Therapeutics, Inc. | 0.64% | $58m |
| 39 | Apogee Therapeutics, Inc. | 0.59% | $54m |
| 40 | Protagonist Therapeutics, Inc. | 0.58% | $53m |
| 41 | Rhythm Pharmaceuticals, Inc. | 0.57% | $52m |
| 42 | Repligen Corp. | 0.57% | $52m |
| 43 | Spyre Therapeutics, Inc. | 0.54% | $49m |
| 44 | Bruker Corp. | 0.52% | $47m |
| 45 | PTC Therapeutics, Inc. | 0.51% | $46m |
| 46 | Nuvalent, Inc. | 0.50% | $46m |
| 47 | Twist Bioscience Corp. | 0.48% | $43m |
| 48 | Tempus AI, Inc. | 0.48% | $43m |
| 49 | Mirum Pharmaceuticals, Inc. | 0.45% | $41m |
| 50 | Cogent Biosciences, Inc. | 0.44% | $40m |
| 51 | Xenon Pharmaceuticals, Inc. | 0.43% | $39m |
| 52 | Scholar Rock Holding Corp. | 0.41% | $38m |
| 53 | Travere Therapeutics, Inc. | 0.40% | $36m |
| 54 | Definium Therapeutics, Inc. | 0.38% | $35m |
| 55 | CRISPR Therapeutics AG | 0.38% | $35m |
| 56 | Oruka Therapeutics, Inc. | 0.38% | $34m |
| 57 | Veracyte, Inc. | 0.36% | $32m |
| 58 | 10X Genomics, Inc. | 0.34% | $31m |
| 59 | Legend Biotech Corp. | 0.33% | $30m |
| 60 | ACADIA Pharmaceuticals, Inc. | 0.33% | $30m |
| 61 | CG oncology, Inc. | 0.32% | $29m |
| 62 | Denali Therapeutics, Inc. | 0.30% | $27m |
| 63 | Crinetics Pharmaceuticals, Inc. | 0.29% | $26m |
| 64 | Erasca, Inc. | 0.27% | $24m |
| 65 | Tango Therapeutics, Inc. | 0.26% | $23m |
| 66 | Adaptive Biotechnologies Corp. | 0.26% | $23m |
| 67 | ImmunityBio, Inc. | 0.26% | $23m |
| 68 | Beam Therapeutics, Inc. | 0.25% | $23m |
| 69 | Edgewise Therapeutics, Inc. | 0.25% | $23m |
| 70 | Structure Therapeutics, Inc. | 0.24% | $22m |
| 71 | Immunovant, Inc. | 0.24% | $22m |
| 72 | Ideaya Biosciences, Inc. | 0.24% | $22m |
| 73 | Ultragenyx Pharmaceutical, Inc. | 0.23% | $21m |
| 74 | Dyne Therapeutics, Inc. | 0.23% | $21m |
| 75 | Arcutis Biotherapeutics, Inc. | 0.23% | $21m |
| 76 | Newamsterdam Pharma Co. NV | 0.21% | $19m |
| 77 | GRAIL, Inc. | 0.21% | $19m |
| 78 | Relay Therapeutics, Inc. | 0.21% | $19m |
| 79 | uniQure NV | 0.20% | $18m |
| 80 | Arcus Biosciences, Inc. | 0.20% | $18m |
| 81 | Tarsus Pharmaceuticals, Inc. | 0.20% | $18m |
| 82 | Vera Therapeutics, Inc. | 0.20% | $18m |
| 83 | Enliven Therapeutics, Inc. | 0.19% | $17m |
| 84 | Nurix Therapeutics, Inc. | 0.19% | $17m |
| 85 | Alumis, Inc. | 0.18% | $17m |
| 86 | Kodiak Sciences, Inc. | 0.18% | $16m |
| 87 | Vericel Corp. | 0.18% | $16m |
| 88 | Intellia Therapeutics, Inc. | 0.17% | $16m |
| 89 | Caris Life Sciences, Inc. | 0.17% | $15m |
| 90 | BioCryst Pharmaceuticals, Inc. | 0.17% | $15m |
| 91 | Agios Pharmaceuticals, Inc. | 0.16% | $15m |
| 92 | Disc Medicine, Inc. | 0.16% | $14m |
| 93 | Summit Therapeutics, Inc. | 0.15% | $14m |
| 94 | Aurinia Pharmaceuticals, Inc. | 0.15% | $14m |
| 95 | ADMA Biologics, Inc. | 0.15% | $13m |
| 96 | Biohaven Ltd. | 0.15% | $13m |
| 97 | Zymeworks, Inc. | 0.14% | $13m |
| 98 | AnaptysBio, Inc. | 0.14% | $13m |
| 99 | AbCellera Biologics, Inc. | 0.14% | $13m |
| 100 | Sarepta Therapeutics, Inc. | 0.14% | $13m |
| 101 | Syndax Pharmaceuticals, Inc. | 0.14% | $12m |
| 102 | Trevi Therapeutics, Inc. | 0.14% | $12m |
| 103 | Recursion Pharmaceuticals, Inc. | 0.13% | $12m |
| 104 | Zai Lab Ltd. | 0.13% | $12m |
| 105 | Amylyx Pharmaceuticals, Inc. | 0.13% | $12m |
| 106 | Mineralys Therapeutics, Inc. | 0.13% | $12m |
| 107 | Fortrea Holdings, Inc. | 0.13% | $12m |
| 108 | Taysha Gene Therapies, Inc. | 0.13% | $11m |
| 109 | MBX Biosciences, Inc. | 0.13% | $11m |
| 110 | Stoke Therapeutics, Inc. | 0.13% | $11m |
| 111 | Iovance Biotherapeutics, Inc. | 0.13% | $11m |
| 112 | Novocure Ltd. | 0.12% | $11m |
| 113 | Grifols SA | 0.12% | $11m |
| 114 | AtaiBeckley, Inc. | 0.12% | $11m |
| 115 | Absci Corp. | 0.12% | $11m |
| 116 | Compass Pathways plc | 0.12% | $11m |
| 117 | UroGen Pharma Ltd. | 0.12% | $11m |
| 118 | Novavax, Inc. | 0.12% | $10m |
| 119 | Tyra Biosciences, Inc. | 0.11% | $10m |
| 120 | Monte Rosa Therapeutics, Inc. | 0.11% | $10m |
| 121 | Nuvation Bio, Inc. | 0.11% | $9.9m |
| 122 | Vir Biotechnology, Inc. | 0.11% | $9.7m |
| 123 | Immunocore Holdings plc | 0.10% | $9.5m |
| 124 | CareDx, Inc. | 0.10% | $9.4m |
| 125 | GH Research plc | 0.10% | $9.3m |
| 126 | MannKind Corp. | 0.097% | $8.9m |
| 127 | Lakefront Biotherapeutics NV | 0.097% | $8.8m |
| 128 | Rapport Therapeutics, Inc. | 0.092% | $8.4m |
| 129 | Sionna Therapeutics, Inc. | 0.090% | $8.2m |
| 130 | ArriVent Biopharma, Inc. | 0.088% | $8.0m |
| 131 | Xencor, Inc. | 0.087% | $7.9m |
| 132 | Bicara Therapeutics, Inc. | 0.087% | $7.9m |
| 133 | Inhibrx Biosciences, Inc. | 0.080% | $7.3m |
| 134 | Maze Therapeutics, Inc. | 0.080% | $7.2m |
| 135 | Pharvaris NV | 0.079% | $7.2m |
| 136 | WaVe Life Sciences Ltd. | 0.076% | $6.9m |
| 137 | Stevanato Group SpA | 0.074% | $6.7m |
| 138 | Mesoblast Ltd. | 0.074% | $6.7m |
| 139 | MeiraGTx Holdings plc | 0.074% | $6.7m |
| 140 | Corvus Pharmaceuticals, Inc. | 0.073% | $6.7m |
| 141 | Kura Oncology, Inc. | 0.073% | $6.6m |
| 142 | Septerna, Inc. | 0.071% | $6.5m |
| 143 | Precigen, Inc. | 0.070% | $6.4m |
| 144 | Olema Pharmaceuticals, Inc. | 0.069% | $6.2m |
| 145 | Janux Therapeutics, Inc. | 0.068% | $6.2m |
| 146 | Replimune Group, Inc. | 0.066% | $6.0m |
| 147 | Zevra Therapeutics, Inc. | 0.065% | $5.9m |
| 148 | Personalis, Inc. | 0.064% | $5.9m |
| 149 | Alto Neuroscience, Inc. | 0.064% | $5.8m |
| 150 | Cullinan Therapeutics, Inc. | 0.064% | $5.8m |
| 151 | Theravance Biopharma, Inc. | 0.064% | $5.8m |
| 152 | Annexon, Inc. | 0.063% | $5.8m |
| 153 | Zenas Biopharma, Inc. | 0.063% | $5.7m |
| 154 | Geron Corp. | 0.062% | $5.7m |
| 155 | Solid Biosciences, Inc. | 0.061% | $5.5m |
| 156 | BioAge Labs, Inc. | 0.060% | $5.5m |
| 157 | Arbutus Biopharma Corp. | 0.059% | $5.3m |
| 158 | Castle Biosciences, Inc. | 0.055% | $5.0m |
| 159 | Rigel Pharmaceuticals, Inc. | 0.054% | $4.9m |
| 160 | Ironwood Pharmaceuticals, Inc. | 0.052% | $4.7m |
| 161 | ORIC Pharmaceuticals, Inc. | 0.051% | $4.7m |
| 162 | Savara, Inc. | 0.051% | $4.6m |
| 163 | Maravai LifeSciences Holdings, Inc. | 0.051% | $4.6m |
| 164 | Sana Biotechnology, Inc. | 0.049% | $4.5m |
| 165 | CytomX Therapeutics, Inc. | 0.049% | $4.4m |
| 166 | 4D Molecular Therapeutics, Inc. | 0.048% | $4.4m |
| 167 | Phathom Pharmaceuticals, Inc. | 0.048% | $4.4m |
| 168 | Candel Therapeutics, Inc. | 0.047% | $4.2m |
| 169 | Aclaris Therapeutics, Inc. | 0.045% | $4.1m |
| 170 | REGENXBIO, Inc. | 0.044% | $4.0m |
| 171 | OPKO Health, Inc. | 0.044% | $4.0m |
| 172 | Altimmune, Inc. | 0.043% | $3.9m |
| 173 | Design Therapeutics, Inc. | 0.042% | $3.8m |
| 174 | Allogene Therapeutics, Inc. | 0.041% | $3.8m |
| 175 | Cytek Biosciences, Inc. | 0.041% | $3.7m |
| 176 | Myriad Genetics, Inc. | 0.039% | $3.6m |
| 177 | ARS Pharmaceuticals, Inc. | 0.039% | $3.5m |
| 178 | Ginkgo Bioworks Holdings, Inc. | 0.039% | $3.5m |
| 179 | Contineum Therapeutics, Inc. | 0.037% | $3.4m |
| 180 | Pacific Biosciences of California, Inc. | 0.037% | $3.4m |
| 181 | C4 Therapeutics, Inc. | 0.036% | $3.3m |
| 182 | Aura Biosciences, Inc. | 0.036% | $3.2m |
| 183 | Sagimet Biosciences, Inc. | 0.035% | $3.2m |
| 184 | Arvinas, Inc. | 0.035% | $3.2m |
| 185 | Cabaletta Bio, Inc. | 0.034% | $3.1m |
| 186 | Prothena Corp. plc | 0.034% | $3.1m |
| 187 | Alvotech SA | 0.034% | $3.1m |
| 188 | Emergent BioSolutions, Inc. | 0.032% | $2.9m |
| 189 | Enanta Pharmaceuticals, Inc. | 0.031% | $2.8m |
| 190 | Neurogene, Inc. | 0.031% | $2.8m |
| 191 | Fulgent Genetics, Inc. | 0.029% | $2.6m |
| 192 | Rocket Pharmaceuticals, Inc. | 0.027% | $2.5m |
| 193 | Prime Medicine, Inc. | 0.027% | $2.5m |
| 194 | Vanda Pharmaceuticals, Inc. | 0.027% | $2.5m |
| 195 | Kyverna Therapeutics, Inc. | 0.026% | $2.4m |
| 196 | BridgeBio Oncology Therapeutics, Inc. | 0.026% | $2.3m |
| 197 | Tectonic Therapeutic, Inc. | 0.025% | $2.3m |
| 198 | Autolus Therapeutics plc | 0.025% | $2.3m |
| 199 | Editas Medicine, Inc. | 0.025% | $2.2m |
| 200 | Standard BioTools, Inc. | 0.024% | $2.2m |
| 201 | Perspective Therapeutics, Inc. | 0.024% | $2.2m |
| 202 | Silence Therapeutics plc | 0.022% | $2.0m |
| 203 | OmniAb, Inc. | 0.022% | $2.0m |
| 204 | Atea Pharmaceuticals, Inc. | 0.022% | $2.0m |
| 205 | Lexeo Therapeutics, Inc. | 0.022% | $2.0m |
| 206 | Immuneering Corp. | 0.021% | $1.9m |
| 207 | Upstream Bio, Inc. | 0.020% | $1.8m |
| 208 | Lineage Cell Therapeutics, Inc. | 0.019% | $1.7m |
| 209 | Anavex Life Sciences Corp. | 0.018% | $1.6m |
| 210 | Fulcrum Therapeutics, Inc. | 0.016% | $1.5m |
| 211 | Keros Therapeutics, Inc. | 0.015% | $1.4m |
| 212 | Codexis, Inc. | 0.015% | $1.3m |
| 213 | Arcturus Therapeutics Holdings, Inc. | 0.014% | $1.2m |
| 214 | Voyager Therapeutics, Inc. | 0.013% | $1.2m |
| 215 | Quanterix Corp. | 0.013% | $1.2m |
| 216 | NovaBridge Biosciences | 0.013% | $1.2m |
| 217 | Larimar Therapeutics, Inc. | 0.012% | $1.1m |
| 218 | Pyxis Oncology, Inc. | 0.012% | $1.1m |
| 219 | Humacyte, Inc. | 0.012% | $1.1m |
| 220 | Entrada Therapeutics, Inc. | 0.012% | $1.1m |
| 221 | Caribou Biosciences, Inc. | 0.012% | $1.1m |
| 222 | Tenaya Therapeutics, Inc. | 0.012% | $1.1m |
| 223 | LENZ Therapeutics, Inc. | 0.012% | $1.1m |
| 224 | Foghorn Therapeutics, Inc. | 0.012% | $1.1m |
| 225 | Quantum-Si, Inc. | 0.012% | $1.1m |
| 226 | AC Immune SA | 0.011% | $1.0m |
| 227 | Bicycle Therapeutics plc | 0.011% | $1.0m |
| 228 | Neumora Therapeutics, Inc. | 0.010% | $924,064 |
| 229 | PepGen, Inc. | 0.009% | $807,334 |
| 230 | Lyell Immunopharma, Inc. | 0.008% | $759,698 |
| 231 | ADC Therapeutics SA | 0.008% | $715,768 |
| 232 | Cellectis SA | 0.007% | $669,342 |
| 233 | Black Diamond Therapeutics, Inc. | 0.007% | $642,165 |
| 234 | Aardvark Therapeutics, Inc. | 0.006% | $513,354 |
| 235 | Alpha Teknova, Inc. | 0.005% | $438,297 |
| 236 | Jyong Biotech Ltd. | 0.005% | $424,783 |
| 237 | Immutep Ltd. | 0.003% | $305,795 |
| 238 | Gossamer Bio, Inc. | 0.003% | $247,084 |
| 239 | Third Harmonic Bio, Inc. | 0.000% | $1 |
Weights are each holding's share of the fund's net assets, as filed; they add up to 99.88%, with the rest in positions that are not common stock. Values are in US dollars.
What has been filed or recorded for iShares Biotechnology ETF (IBB)?
The filings we hold for iShares Biotechnology ETF, newest first: 12 fails-to-deliver days, the latest dated 29 Oct 2026.
| And | ||||
|---|---|---|---|---|
| 29 Oct 2026 | Fails to deliver | Shares failed to deliver | 518 shares | 112K USD notional |
| 28 Oct 2026 | Fails to deliver | Shares failed to deliver | 5,561 shares | 1.2M USD notional |
| 26 Oct 2026 | Fails to deliver | Shares failed to deliver | 11,291 shares | 2.3M USD notional |
| 22 Oct 2026 | Fails to deliver | Shares failed to deliver | 5,524 shares | 1.2M USD notional |
| 21 Oct 2026 | Fails to deliver | Shares failed to deliver | 2,850 shares | 600K USD notional |
| 20 Oct 2026 | Fails to deliver | Shares failed to deliver | 57 shares | 12K USD notional |
| 19 Oct 2026 | Fails to deliver | Shares failed to deliver | 32,043 shares | 6.5M USD notional |
| 16 Oct 2026 | Fails to deliver | Shares failed to deliver | 189 shares | 39K USD notional |
| 15 Oct 2026 | Fails to deliver | Shares failed to deliver | 3,140 shares | 638K USD notional |
| 13 Oct 2026 | Fails to deliver | Shares failed to deliver | 114,404 shares | 23.4M USD notional |
| 09 Oct 2026 | Fails to deliver | Shares failed to deliver | 43,748 shares | 8.8M USD notional |
| 07 Oct 2026 | Fails to deliver | Shares failed to deliver | 2,502 shares | 508K USD notional |
What is Reddit saying about iShares Biotechnology ETF (IBB)?
Reddit mentioned IBB 5 times in the 30 days to 21 November 2026, across 2 of the communities we track. All of them were scored for sentiment: 80% read bullish, 0% bearish and 20% neither. Reddit data updated 21 November 2026.
30-day window, Method
How do Reddit mentions of iShares Biotechnology ETF (IBB) compare with its price?
Share ↗
Which subreddits are talking about iShares Biotechnology ETF (IBB)?
30 days
What do people ask about iShares Biotechnology ETF (IBB)?
What did iShares Biotechnology ETF close at?199.73
iShares Biotechnology ETF closed at 199.73 USD on 20 Nov 2026, down 1.96% on the close before. That is the end-of-day price from Finazon, not a live quote.
Has iShares Biotechnology ETF had fails-to-deliver recently?518 shares
Yes. The most recent SEC fails-to-deliver record for iShares Biotechnology ETF is dated 29 Oct 2026, when 518 shares failed to deliver. See Filings
What exchange is iShares Biotechnology ETF listed on?
iShares Biotechnology ETF trades on NASDAQ under the ticker IBB.
What is Reddit saying about iShares Biotechnology ETF?1 mentions
iShares Biotechnology ETF was mentioned 1 times in the last 7 days across the finance subreddits we track, and 5 times over the trailing 30 days. Of the 5 mentions scored for sentiment, 80% read bullish and 0% bearish. That is a social signal, not investment advice. See Reddit

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- RedditReddit ingest across the tracked finance subreddits
- SECSEC fails-to-deliver (CNS) data
- SEC N-PORTSEC Form N-PORT, the fund's own monthly portfolio report
- SEC filingAbout text: the fund's prospectus filed with the SEC, summarised in our own words